Eden Research plc - Appointment of Global Head of Biology and Dev
("Eden" or "Company")
Appointment of Global Head of Biology and Development
Aoife joins Eden from Plant Health Care, a leading provider of scientifically proven biological products for the agricultural industry, where she has been Technical Director for the
At Eden, she will undertake global responsibility for developing the Company's product pipeline from a biology standpoint, working closely with a growing R&D team. Her appointment follows the opening of Eden's new laboratory, where the Company will conduct in-house processes for developing and screening new products. Aoife will be heavily involved in assessing the efficacy and safety of new formulations and running commercial scale trials focused on plant biology for the environment and sustainability. Aoife will also work closely with Eden's commercial partners in order to support their efforts and ultimately grow the list of authorised uses for Eden's product portfolio.
Aoife has considerable regulatory affairs experience in plant protection products and biostimulants, as well as experience running coordinated crop trials internationally for over 20 years. During her career, she has had roles at BASF,
For further information contact:
| || |
01285 359 555
Cenkos Securities plc (Nominated advisor and broker)
| || |
020 7397 8900
| || |
Eden's Sustaine encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can be used with both natural and synthetic compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. They produce stabilised aqueous suspensions which, are easy to mix and apply, have phased release patterns, are safer for the environment and the crops themselves.
By 2025 in the EU, pesticides containing synthetic polymer microplastics are likely to be banned and removed from the market. The only acceptable alternative is the substitution with biodegradable formulations. Reformulated products will need to be evaluated and registered within the five-year transition period.
Sustaine is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Sustaine provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of 14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.
Mevalone is a foliar fungicide which has been authorised for sale in
Cedroz is a nematicide which has been authorised for sale in
Eden was admitted to trading on AIM on
This information is provided by RNS, the news service of the
Quick facts: Eden Research PLC
Market Cap: £32.33 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE